Heineken warns UK pubs of beer sales hit from GLP-1 weight-loss drugs

Heineken, the world's second-largest brewer, has warned British hospitality clients that the rising use of GLP-1 drugs like Ozempic and Wegovy may reduce alcohol consumption, potentially lowering beer and cider sales. The claim is based on a company presentation and reflects an emerging consumer trend rather than confirmed sales data. This matters as it signals potential demand shifts for the beverage industry and could impact Heineken's revenue outlook.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works